Impact of statin-ezetimibe combination in chronic kidney disease
Over the decades, statin therapy, which reduces serum levels of low-density lipoprotein cholesterol (LDL-c), has been proved to reduce cardiovascular events by stabilizing atherosclerotic plaques; however, the risks are still residual [1 –3]. In such situation, we should consider not only LDL-c, but also other lipid profiles, including triglyceride, remnant-like particle cholesterol (RLP-c), and high-density lipoprotein cholesterol (HDL-c).
Source: International Journal of Cardiology - Category: Cardiology Authors: Yoshihiro Fukumoto Tags: Editorial Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Chronic Kidney Disease | Heart | Statin Therapy | Urology & Nephrology | Vytorin | Zetia